Mezzion Pharma Co.Ltd (140410) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has a cash flow conversion efficiency ratio of -0.076x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.83 Billion ≈ $-1.92 Million USD) by net assets (₩37.35 Billion ≈ $25.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mezzion Pharma Co.Ltd - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Mezzion Pharma Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 140410 total debt and obligations for a breakdown of total debt and financial obligations.
Mezzion Pharma Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Upstream Bio, Inc.
NASDAQ:UPB
|
-0.059x |
|
Altia Consultores S.A.
MC:ALC
|
0.062x |
|
Chang Lan Electric Technology Co Ltd
SHE:002879
|
0.000x |
|
Aekyung Petrochemical Co Ltd
KO:161000
|
0.026x |
|
Braiin Limited Common Stock
NASDAQ:BRAI
|
N/A |
|
Shanghai Yongguan Adhesive Products Corp Ltd
SHG:603681
|
0.119x |
|
TPI Polene Public Company Limited
BK:TPIPL
|
0.022x |
|
Flotek Industries Inc
NYSE:FTK
|
0.055x |
Annual Cash Flow Conversion Efficiency for Mezzion Pharma Co.Ltd (2012–2024)
The table below shows the annual cash flow conversion efficiency of Mezzion Pharma Co.Ltd from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 140410 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩46.06 Billion ≈ $31.22 Million |
₩-18.49 Billion ≈ $-12.53 Million |
-0.401x | -123.74% |
| 2023-12-31 | ₩61.44 Billion ≈ $41.64 Million |
₩-11.02 Billion ≈ $-7.47 Million |
-0.179x | +61.01% |
| 2022-12-31 | ₩26.24 Billion ≈ $17.78 Million |
₩-12.07 Billion ≈ $-8.18 Million |
-0.460x | -91.72% |
| 2021-12-31 | ₩62.79 Billion ≈ $42.55 Million |
₩-15.07 Billion ≈ $-10.21 Million |
-0.240x | -84.84% |
| 2020-12-31 | ₩56.81 Billion ≈ $38.50 Million |
₩-7.38 Billion ≈ $-5.00 Million |
-0.130x | +73.36% |
| 2019-12-31 | ₩42.83 Billion ≈ $29.03 Million |
₩-20.88 Billion ≈ $-14.15 Million |
-0.488x | -28.63% |
| 2018-12-31 | ₩57.32 Billion ≈ $38.84 Million |
₩-21.72 Billion ≈ $-14.72 Million |
-0.379x | -52.50% |
| 2017-12-31 | ₩53.17 Billion ≈ $36.03 Million |
₩-13.21 Billion ≈ $-8.95 Million |
-0.249x | -115.96% |
| 2016-12-31 | ₩52.81 Billion ≈ $35.79 Million |
₩-6.08 Billion ≈ $-4.12 Million |
-0.115x | -506.08% |
| 2015-12-31 | ₩62.54 Billion ≈ $42.38 Million |
₩1.77 Billion ≈ $1.20 Million |
0.028x | -42.77% |
| 2012-12-31 | ₩63.34 Billion ≈ $42.92 Million |
₩3.14 Billion ≈ $2.13 Million |
0.050x | -- |
About Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more